Ritter Pharmaceuticals, Inc. Announces First Patient Enrollment in Its Phase 2 Clinical Study of RP-G28 for the Treatment of Lactose Intolerance
LOS ANGELES, CA--(Marketwire - June 21, 2011) -
RP-G28 has the potential to become the first prescription drug approved for treating the symptoms of lactose intolerance, which affects more than 80 million people in the United States and 4.3 billion people worldwide.
"Based on the promising results from our development work, we are excited to initiate this clinical study which is designed to more fully characterize the therapeutic potential of RP-G28 in treating lactose intolerance," said Ritter's President & CEO Andrew Ritter. "This is an important next step toward making RP-G28 available to lactose intolerance sufferers around the world."
For additional information, including a list of the Research Centers conducting Ritter's Phase 2 Clinical Study in Honolulu, Hawaii and Dallas, Texas, visit www.ClinicalTrials.gov
About Lactose Intolerance
Lactose intolerance is the inability to digest dairy products, such as milk, ice cream, cheese and pizza. Symptoms typically occur after eating foods with lactose and frequently cause problems in the digestive or gastrointestinal (GI) system.
About Ritter Pharmaceuticals, Inc.
Ritter is committed to the discovery, development and commercialization of innovative therapies for GI disorders. The Company's scientific platform of GI physiology, metabolism and gut adaptation brings creativity to providing unique therapeutic approaches to a variety of disorders, including lactose intolerance, irritable bowel syndrome, inflammatory bowel disease, and traveler's diarrhea. Ritter's mission is to help individuals live a healthier and happier lifestyle through improved digestion and overall well being.
Director of Operations
Ritter Pharmaceuticals, Inc.